Enfoque actual del tratamiento crónico del asma bronquial

Autores/as

  • Ronald Chacon Chaves Caja Costarricense del Seguro Social, Hospital Dr. Rafael A. Calderón Guardia
  • Marlene Jiménez Carro Caja Costarricense del Seguro Social, Hospital Dr. Rafael A. Calderón Guardia

DOI:

https://doi.org/10.51481/amc.v40i1.578

Palabras clave:

Asma bronquial, tratamiento, lineamientos

Resumen

En los últimos años se han producido grandes avances en el entendimiento de la fisiopatología del asma bronquial, y esto a su vez ha causado cambios significativos en el enfoque del tratamiento crónico del paciente asmático...

Citas

British Thoracic Society, The National Asthma Campaign, The Royal College of Physicians of London, et al. The British guidelines on asthma management, 1995 review and position statement. Thorax. 1997; 52,Suppl.

National Heart, Lung and Blood Institute/World Health Organization. Global strategy for asthma management and prevention. 1995. Workshop Report Publication No. 3659.

National Institutes of Health; National Heart, Lung and Blood Institute. Guidelines for the diagnosis and management of asthma. Expert Panel Report

Bethesda Md. April 1997. (NIH Publication No. 97-4051) 4. Sly, RM. New guidelines for diagnosis and management of asthma. Ann Allergy Asthma Immunol. 1997; 78:427-437.

Holgate ST. The cellular and mediator basis Of asthma in relation to natural history. Lancet. 1997; 350(suppl 11):5-9.

Van Schayck CR Cloosterman SGM, Hofland ID, Van Herwaarden CLA. How detrimental is chronic use of bronchodilators in asthma and chronic obstructive pulmonary disease?. Am J Respir Crit Care Med. 1995: 151: 13171319.

Suissa S, Hernrnelgarn B, Blais L. Ernst P. Bronchodilators and acute cardiac death. Am J Resøir Crit Care Med. 1996: 154:1598-1602.

Leff AR. Identifying patients at risk from the use of Beta-adrenergic agonists. Am J Respir Crit Care Med. 1996; 154:1593.

Spitzer WO, Suissa, Ernst P, Horwitz RI, Habbick B, Cock-croft D, Boivin JF, McNutt M, Buist AS, Rebuck AS. The use of ß-agonists and the risk of death and near death from asthma. N Eng J Med. 1992; 326:501-506.

Crane J, Pearce N. Burgess C, Beasley R. Asthma and the ß agonist debate. Thorax. 1995: 50

Taylor DR, Sears MR. Cockcroft DW. The Beta-agonist controversy. The Medical Clinics of North America. 1996: 80:719-748

Cockcroft DW, y Swystun VA. Functional antagonism; tolerance produced by inhaled B2 agonists. Thorax. 1996; 51:1051-1056.

Connolly MJ, Crowley JJ. Charan NB, Nielson cp, Vestel RE. Reduced subjective awareness of bronchoconstriction provoked by metacholine in elderly asthmatic and normal subjects as measured on a simple awareness scale. Thorax. 1992; 47:410-413.

Corbridge TC, y Hall JB. The assessment and management of adults with status asthmaticus. Am J Respir Crit Care Med. 1995: 151:1296-1316. 15. Abou-Shala N. MacIntyre N. Emergent management Of acute asthma. The Medical Clinics of North America. 1996; 80:677-699.

Lipworth BJ. Treatment of acute asthma. Lancet. 1997: 350(suppl Il): 1823.

Sporik R, Holgate S, Plans-Mill TAAE. Cogswell J. Exposure to house dust mite allergen (Der p I) and the development of asthma in childhood. N Eng J Med. 1990; 323502-507.

Arshad SH, Mathews S. Grant C, Hide DW. Effect Of allergen avoidance on the development of allergie disorders in infancy. Lancet. 1992; 339:14931497.

Wardlaw A. The role Of air pollution in asthma. Clin Exp Allergy. 1993: 23:81-96.

Wilson R. Influenza vaccination. Thorax. 1994: 49:1079-1080. editorial.

Watson JM, Cordier JF, Nicholson KG. Does influenza cause exacerbations of chronic airflow obstruction or asthma?. Thorax. 1997: 52: 190-194.

Becklake MR. Ernst P Asthma: Environmental factors. Lancet. 1997: 350

von Mutius E. Asthma: Towards prevention. Lancet. 199T,

Bone RC. Goals of asthma management. A step-care approach. Chest 1996; 109:1056-1065.

Norman PS, Barnes PJ. Is there a role for immunotherapy in the treatment of asthma. Am J Respir crit care Med. 1996; 154:1225-1228.

Douglass JA, Thien FCK, O' Hehir RE. Immunotherapy in asthma Thorax. 1997: S2

Creticos PS, Reed CE. Norman PS, Khoury J. Adkinson NF. Buncher CR. et al. Ragweed Immunotherapy in asthma. N Engl J Med. 1996: 334:501-506

Kidney J, Dominguez M, Taylor PM, Rose M. Chung KF, Barnes Inuuunomodulation by theophylline in Isthma. Demonstration by withdrawal of therapy. Am J Respir crit Care Med. 1995; 151 :1907-1914.

Christie PE. NC Barnes. Leukotriene B4 and asthma. Thorax. 1996. 51:1171-1 173

Taylor 1K. Cysteinyl leukotrienes in asthma: current state of therapeutic evaluation.. Thorax. 1995: 50:1005-1010.

Pauwels et al. Advances in the treatment of asthlna: focus on Zafirlukasl Drugs. 1996: 52:suppl.6.

Robusehi M. Riva E. Succella L. Vida E. Bar-nave R. Rosi M. et Prevention Of exercise induced bronchoconstriction by a new leukotliene antagonist (SK & F 104353): a double blind study versus disodium cromoglycate and placebo. Am Rev Respir Dis. 1992: 145: 1285-1288

Kidney JC. Ridge SM. Chung KF, Barnes PJ. Inhibition of platelet activating factor-induced bronchoconstriction by the leukotriene D4 receptor antagonist ICI 204219. Am Rev Respir Dis. 1993; 147215-217.

Yalnamoto H. Nagata M, Kwamitsu K, Tabe K. Kiuchi H. Sakalnoto Y. al. Inhibition of analgesic-induced asthma by leukotriene receptor antagomsa ONO-1078. Am J Respir Crit Care Med. 1994: 150:254-257.

Spector SL. Smith LJ. Glæss M. Effects of six weeks of therapy with or-ai doses Of ICI 204219. a leukotriene D4 receptor antagonist. in subjects bronchial asthma. Am J Respir Crit Care Med, 1994:

Hill JM, y Tattertsfield AE. Corticosteroid sparing agents in asthnu Thorax. 1995: 50: 577-582.

Lynch JR McCune WJ. Immunosuppressive and cytotor• pharmacotherapy. Am J Respir Crit Care. 1997:

Descargas

Publicado

1998-03-01

Cómo citar

Chacon Chaves, R., & Jiménez Carro, M. (1998). Enfoque actual del tratamiento crónico del asma bronquial. Acta Médica Costarricense , 40(1), 5-10. https://doi.org/10.51481/amc.v40i1.578

Artículos similares

También puede {advancedSearchLink} para este artículo.